PE20001464A1 - Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos - Google Patents
Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenosInfo
- Publication number
- PE20001464A1 PE20001464A1 PE2000000103A PE0001032000A PE20001464A1 PE 20001464 A1 PE20001464 A1 PE 20001464A1 PE 2000000103 A PE2000000103 A PE 2000000103A PE 0001032000 A PE0001032000 A PE 0001032000A PE 20001464 A1 PE20001464 A1 PE 20001464A1
- Authority
- PE
- Peru
- Prior art keywords
- cr13r14
- quinolin
- methyl
- ona
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE QUINOLIN 2-ONA SUSTITUIDOS CON HETEROARILO DE FORMULA I, DONDE: R1 ES H, ALQUILO C1-C10, (CR13R14)qCOR12, (CR13R14)qCOOR15, (CR13R14)qOR12, (CR13R14)t(CICLOALQUILO C3-C10), ENTRE OTROS; R2 ES HALOGENO, CIANO, COOR15; R3, R4, R5, R6, R7 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10, HALOGENO, CIANO, NITRO, TRIFLUOROMETILO, TRIFLUOROMETOXI, AZIDO, OR12, COR12, COOR12, ENTRE OTROS; Z ES UN HETEROCICLO AROMATICO C4-C10 DE 4-10 MIEMBROS; R8 ES H, OR12, OCOR12, NR12R13, N=CR12R13, NR12COR13, CIANO, COOR13, SR12, ENTRE OTROS; R9 ES (CR13R14)t(IMIDAZOLILO), (CR13R14)t(PIRIDINILO); R12 SON H, ALQUILO C1-C10, (CR13R14)t(CICLOALQUILO C3-C10), (CR13R14)t(ARILO C6-C10), (CR13R14)t(HETEROCICLO), ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C6, (CR13R14)q, (CR13R14)t; R15 ES R12 EXCEPTO H. SON COMPUESTOS PREFERIDOS 6-[AMINO-(6-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4-(3-CLORO-FENIL)-1-METIL-1H-QUINOLIN-2-ONA (ENANTIOMERA A o B), 4-(3-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-1-CICLOPROPILMETIL-1H-QUINOLIN-2-ONA, ENTRE OTROS. LOS DERIVADOS DE QUINOLIN-2-ONA INHIBEN A LA FARNESIL TRANSFERASA POR LO QUE PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS COMO CANCER DE PULMON, CANCER DE HUESOS, CANCER PANCREATICO, CANCER DE PIEL, CANCER DE CABEZA Y CUELLO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11970299P | 1999-02-11 | 1999-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20001464A1 true PE20001464A1 (es) | 2000-12-20 |
Family
ID=22385869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000103A PE20001464A1 (es) | 1999-02-11 | 2000-02-10 | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos |
Country Status (39)
Country | Link |
---|---|
US (3) | US6258824B1 (es) |
EP (1) | EP1150973B1 (es) |
JP (3) | JP4090200B2 (es) |
KR (1) | KR20010102073A (es) |
CN (1) | CN1340051A (es) |
AP (1) | AP2001002241A0 (es) |
AR (1) | AR028985A1 (es) |
AT (1) | ATE297916T1 (es) |
AU (1) | AU2124800A (es) |
BG (1) | BG105860A (es) |
BR (1) | BR0008202A (es) |
CA (1) | CA2362394C (es) |
CO (1) | CO5140097A1 (es) |
CZ (1) | CZ20012910A3 (es) |
DE (1) | DE60020812T2 (es) |
DZ (1) | DZ3009A1 (es) |
EA (1) | EA200100766A1 (es) |
EE (1) | EE200100425A (es) |
ES (1) | ES2243228T3 (es) |
GT (1) | GT200000014A (es) |
HK (1) | HK1042096A1 (es) |
HN (1) | HN2000000019A (es) |
HR (1) | HRP20010574A2 (es) |
HU (1) | HUP0105231A3 (es) |
ID (1) | ID29584A (es) |
IL (1) | IL144307A0 (es) |
IS (1) | IS5997A (es) |
MA (1) | MA26718A1 (es) |
NO (1) | NO20013909L (es) |
OA (1) | OA11833A (es) |
PA (1) | PA8490601A1 (es) |
PE (1) | PE20001464A1 (es) |
PL (1) | PL349839A1 (es) |
SK (1) | SK11002001A3 (es) |
SV (1) | SV2001000020A (es) |
TN (1) | TNSN00028A1 (es) |
TR (2) | TR200201297T2 (es) |
WO (1) | WO2000047574A1 (es) |
ZA (1) | ZA200106520B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04582B1 (et) * | 1998-07-06 | 2006-02-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis |
TR200201297T2 (tr) * | 1999-02-11 | 2002-06-21 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. |
ATE260269T1 (de) | 1999-11-05 | 2004-03-15 | Cytovia Inc | Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung |
ES2212971T3 (es) * | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
WO2001054688A1 (en) * | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
ES2261476T3 (es) | 2000-09-25 | 2006-11-16 | Janssen Pharmaceutica N.V. | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. |
AU2002220559A1 (en) * | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
EP1322636A1 (en) | 2000-09-25 | 2003-07-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives |
JP4974439B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体 |
PL360677A1 (en) * | 2000-10-02 | 2004-09-20 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
EP1339709B1 (en) | 2000-11-21 | 2009-06-24 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting benzoheterocyclic derivatives |
JP4351444B2 (ja) * | 2000-12-27 | 2009-10-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する4−ヘテロシクリル−キノリンおよびキナゾリン誘導体 |
ATE319704T1 (de) | 2000-12-27 | 2006-03-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate |
EP1392283A4 (en) | 2001-05-16 | 2004-10-20 | Cytovia Inc | COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS |
EP1392683B1 (en) * | 2001-05-16 | 2009-12-02 | Cytovia, Inc. | Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20030139332A1 (en) * | 2001-07-09 | 2003-07-24 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
EP1458720B1 (en) | 2001-12-19 | 2009-03-18 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
DE60314381T2 (de) | 2002-03-22 | 2008-02-21 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren |
MXPA04009435A (es) * | 2002-03-29 | 2005-01-25 | Janssen Pharmaceutica Nv | Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico. |
EP1497295B1 (en) | 2002-04-15 | 2006-08-16 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
EP1509515A4 (en) | 2002-05-16 | 2006-07-05 | Cytovia Inc | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE |
EP1513515A2 (en) | 2002-05-16 | 2005-03-16 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20040186160A1 (en) * | 2002-12-13 | 2004-09-23 | Sugen, Inc. | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors |
NZ540340A (en) * | 2002-12-19 | 2007-07-27 | Pfizer | 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
OA13151A (en) | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
WO2004076446A1 (ja) * | 2003-02-27 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | ベンゾチオフェン誘導体 |
NZ544697A (en) * | 2003-07-22 | 2009-03-31 | Janssen Pharmaceutica Nv | Quinolinone derivatives as inhibitors of c-fms kinase |
EP1691812A4 (en) | 2003-11-20 | 2010-01-13 | Childrens Hosp Medical Center | GTPASE INHIBITORS AND METHOD OF USE |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
US20050288298A1 (en) * | 2004-03-18 | 2005-12-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
PT1784396E (pt) * | 2004-08-26 | 2011-01-27 | Pfizer | Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases |
WO2006021884A2 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
AU2005294430A1 (en) * | 2004-10-07 | 2006-04-20 | Cytovia, Inc. | Substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis |
JP2009508809A (ja) | 2005-07-29 | 2009-03-05 | チルドレンズ ホスピタル メディカル センター | RAC−1GTPaseのGTPase阻害因子とその使用方法およびその結晶構造 |
MY164457A (en) | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
ATE533057T1 (de) | 2005-09-20 | 2011-11-15 | Osi Pharm Inc | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren |
JP2009521470A (ja) * | 2005-12-23 | 2009-06-04 | リンク メディシン コーポレイション | シヌクレイン障害の治療 |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
SG174090A1 (en) | 2006-08-21 | 2011-09-29 | Hoffmann La Roche | Tumor therapy with an anti-vegf antibody |
WO2008144623A1 (en) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
AU2008256926B2 (en) * | 2007-05-23 | 2013-09-19 | Allergan, Inc. | ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists |
US8129356B2 (en) * | 2007-10-01 | 2012-03-06 | Vanderbilt University | Bmx mediated signal transduction in irradiated vascular endothelium |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
MX2011005096A (es) * | 2008-11-13 | 2011-11-18 | Link Medicine Corp | Derivados de azaquinolinona y usos de los mismos. |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2393814A1 (en) | 2009-02-09 | 2011-12-14 | SuperGen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ,エルエルシー | インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
AR093017A1 (es) | 2012-10-16 | 2015-05-13 | Janssen Pharmaceutica Nv | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO |
JP6250686B2 (ja) | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Rorγtのヘテロアリール結合させたキノリニルモジュレータ |
JP6251277B2 (ja) | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ.ベー. | ROR−ガンマ−tのフェニル結合キノリニルモジュレーター |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
CN105308033B (zh) | 2013-03-14 | 2018-08-24 | 特雷罗药物股份有限公司 | Jak2和alk2抑制剂及其使用方法 |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
ES2770727T3 (es) | 2013-10-15 | 2020-07-02 | Janssen Pharmaceutica Nv | Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t |
US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
AU2016364855B2 (en) | 2015-12-03 | 2019-08-29 | Les Laboratoires Servier | MAT2A inhibitors for treating MTAP null cancer |
CN108003150A (zh) * | 2016-10-31 | 2018-05-08 | 河南工业大学 | 4-杂芳基喹啉酮衍生物的制备方法及其应用 |
CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2732531A1 (de) * | 1977-07-19 | 1979-02-01 | Hoechst Ag | Imidazolcarbonsaeuren und deren derivate |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US5136085A (en) * | 1990-11-28 | 1992-08-04 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
US5053543A (en) * | 1990-11-28 | 1991-10-01 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
EP0865440B1 (en) * | 1995-12-08 | 2002-04-03 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
ES2182327T3 (es) * | 1997-06-02 | 2003-03-01 | Janssen Pharmaceutica Nv | Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos. |
NZ509372A (en) | 1998-08-27 | 2003-08-29 | Pfizer Prod Inc | Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer) |
TR200201297T2 (tr) * | 1999-02-11 | 2002-06-21 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. |
-
2000
- 2000-02-04 TR TR2002/01297T patent/TR200201297T2/xx unknown
- 2000-02-04 KR KR1020017010187A patent/KR20010102073A/ko not_active Application Discontinuation
- 2000-02-04 IL IL14430700A patent/IL144307A0/xx unknown
- 2000-02-04 ES ES00901292T patent/ES2243228T3/es not_active Expired - Lifetime
- 2000-02-04 AT AT00901292T patent/ATE297916T1/de not_active IP Right Cessation
- 2000-02-04 ID IDW00200101724A patent/ID29584A/id unknown
- 2000-02-04 SK SK1100-2001A patent/SK11002001A3/sk unknown
- 2000-02-04 DE DE60020812T patent/DE60020812T2/de not_active Expired - Lifetime
- 2000-02-04 WO PCT/IB2000/000121 patent/WO2000047574A1/en active IP Right Grant
- 2000-02-04 CZ CZ20012910A patent/CZ20012910A3/cs unknown
- 2000-02-04 CA CA002362394A patent/CA2362394C/en not_active Expired - Fee Related
- 2000-02-04 EE EEP200100425A patent/EE200100425A/xx unknown
- 2000-02-04 PL PL00349839A patent/PL349839A1/xx not_active Application Discontinuation
- 2000-02-04 CN CN00803668A patent/CN1340051A/zh active Pending
- 2000-02-04 TR TR2002/01296T patent/TR200201296T2/xx unknown
- 2000-02-04 HU HU0105231A patent/HUP0105231A3/hu unknown
- 2000-02-04 JP JP2000598494A patent/JP4090200B2/ja not_active Expired - Fee Related
- 2000-02-04 OA OA1200100212A patent/OA11833A/en unknown
- 2000-02-04 BR BR0008202-3A patent/BR0008202A/pt not_active IP Right Cessation
- 2000-02-04 EA EA200100766A patent/EA200100766A1/ru unknown
- 2000-02-04 AP APAP/P/2001/002241A patent/AP2001002241A0/en unknown
- 2000-02-04 EP EP00901292A patent/EP1150973B1/en not_active Expired - Lifetime
- 2000-02-04 AU AU21248/00A patent/AU2124800A/en not_active Abandoned
- 2000-02-09 TN TNTNSN00028A patent/TNSN00028A1/fr unknown
- 2000-02-09 CO CO00008430A patent/CO5140097A1/es unknown
- 2000-02-09 US US09/501,163 patent/US6258824B1/en not_active Expired - Fee Related
- 2000-02-09 MA MA25905A patent/MA26718A1/fr unknown
- 2000-02-09 DZ DZ000021A patent/DZ3009A1/xx active
- 2000-02-09 HN HN2000000019A patent/HN2000000019A/es unknown
- 2000-02-10 AR ARP000100589A patent/AR028985A1/es not_active Application Discontinuation
- 2000-02-10 PA PA20008490601A patent/PA8490601A1/es unknown
- 2000-02-10 PE PE2000000103A patent/PE20001464A1/es not_active Application Discontinuation
- 2000-02-10 SV SV2000000020A patent/SV2001000020A/es not_active Application Discontinuation
- 2000-02-10 GT GT200000014A patent/GT200000014A/es unknown
-
2001
- 2001-04-17 US US09/836,026 patent/US6388092B2/en not_active Expired - Fee Related
- 2001-07-10 IS IS5997A patent/IS5997A/is unknown
- 2001-07-30 HR HR20010574A patent/HRP20010574A2/hr not_active Application Discontinuation
- 2001-08-08 ZA ZA200106520A patent/ZA200106520B/en unknown
- 2001-08-10 NO NO20013909A patent/NO20013909L/no not_active Application Discontinuation
- 2001-08-30 BG BG105860A patent/BG105860A/xx unknown
-
2002
- 2002-03-07 US US10/092,744 patent/US6710209B2/en not_active Expired - Fee Related
- 2002-05-31 HK HK02104118.7A patent/HK1042096A1/zh unknown
-
2004
- 2004-02-05 JP JP2004029709A patent/JP4216740B2/ja not_active Expired - Fee Related
- 2004-07-20 JP JP2004211298A patent/JP2005002124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20001464A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 | |
PE20180177A1 (es) | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
AR049696A1 (es) | Derivados de indol | |
AR057979A1 (es) | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. | |
PE20090437A1 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
ZA200404022B (en) | Quinazoline(di) ones for invertebrate pest control | |
PE20081530A1 (es) | Nuevos compuestos 617 | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
AR037901A1 (es) | Beta-amino-alfa-cianoacrilatos | |
AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
PE20100718A1 (es) | Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas | |
PE20011259A1 (es) | Derivado de piridina y pirimidina | |
AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
PE20071034A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
PE20091370A1 (es) | Arilpirrolinas insecticidas | |
PE20060316A1 (es) | Derivados de prolina como inhibidores de dipeptidil peptidasa-iv | |
PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
AR067663A1 (es) | Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos. | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
AR037418A1 (es) | Derivados de benzotiazol | |
PE20030761A1 (es) | Derivados del 7-amino-benzotiazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |